ArticleEMBO molecular medicine2022
Concurrent targeting of glycolysis in bacteria and host cell inflammation in septic arthritis.
Article in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Infosomes as Inflammatory Mediators: Proteomic Profiling of Proteins Enriched in Inflammatory Extracellular Vesicles.Molecular & cellular proteomics : MCP · 2026Article
- Glycolytic reprogramming and immune responses in macrophages: a crosstalk driven by bacterial infection.Frontiers in immunology · 2026Review
- Staphylococcus Aureus Tames Nociceptive Neurons to Suppress Synovial Macrophage Responses for Sustained Infection in Septic Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Implant-DerivedAntibiotics (Basel, Switzerland) · 2025Article
- CD44 and CLDN3 as immune-metabolic regulators in acute pancreatitis: a multi-modal transcriptomics study and experimental validation.Frontiers in immunology · 2025Article
- GAPDH-Silence Microsphere via Reprogramming Macrophage Metabolism and eradicating Bacteria for Diabetic infection bone regeneration.Journal of nanobiotechnology · 2024Article
- Dimethyl fumarate covalently modifies Cys673 of NLRP3 to exert anti-inflammatory effects.iScience · 2024Article
- Thwarting resistance: MgrA inhibition with methylophiopogonanone a unveils a new battlefront against S. aureus.NPJ biofilms and microbiomes · 2024Article
- Trained immunity in recurrent Staphylococcus aureus infection promotes bacterial persistence.PLoS pathogens · 2024Article
- Parathyroid hormone therapy improves MRSA-infected fracture healing in a murine diabetic model.Frontiers in cellular and infection microbiology · 2023Article
- Concurrent targeting of glycolysis in bacteria and host cell inflammation in septic arthritis.EMBO molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Intracellular infiltration of bacteria into host cells complicates medical and surgical treatment of bacterial joint infections. Unlike soft tissue infections, septic arthritis and infection-associated inflammation destroy cartilage that does not regenerate once damaged. Herein, we show that glycolytic pathways are shared by methicillin-resistant Staphylococcus aureus (MRSA) proliferation and host inflammatory machinery in septic arthritis. MRSA readily penetrates host cells and induces proinflammatory cascades that persist after conventional antibiotic treatment. The glycolysis-targeting drug dimethyl fumarate (DMF) showed both bacteriostatic and anti-inflammatory effects by hindering the proliferation of intracellular MRSA and dampening excessive intraarticular inflammation. Combinatorial treatment with DMF and vancomycin further reduced the proliferation and re-emergence of intracellular MRSA. Combinatorial adjuvant administration of DMF with antibiotics alleviated clinical symptoms of septic arthritis by suppressing bacterial burden and curbing inflammation to protect cartilage and bone. Our results provide mechanistic insight into the regulation of glycolysis in the context of infection and host inflammation toward development of a novel therapeutic paradigm to ameliorate joint bioburden and destruction in septic arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.